13 Results

People

  1. Lesokhin
    Lesokhin
  2. Panageas
    Panageas
  3. Derkach
    Derkach
  4. Scheinberg
    Scheinberg
  5. Shah
    Shah
  6. Shah
    Shah
  7. Giralt
    Giralt
  8. Hassoun
    Hassoun
  9. Hultcrantz
    Hultcrantz
  10. Korde
    Korde

Groups

  1. Center for Hematologic Malignancies (13)
  2. Department of Medicine (13)
  3. Hematologic Malignancies Research (13)
  4. Hematologic Malignancies, Division of (13)
  5. Population Sciences Research Program (13)
  6. Epidemiology and Biostatistics (12)
  7. Biostatistics Service (11)
  8. GSK Faculty (8)
  9. CTCR Scholars (7)
  10. Sloan Kettering Institute Postdocs (7)
  1. "Hematologic Malignancies Research"
  2. "American Society of Clinical Oncology"
  3. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (3)
Groups
  1. Center for Hematologic Malignancies (13)
  2. Department of Medicine (13)
  3. Hematologic Malignancies Research (13)
  4. Hematologic Malignancies, Division of (13)
  5. Population Sciences Research Program (13)
  6. Epidemiology and Biostatistics (12)

More Groups

People
  1. Alexander Lesokhin (6)
  2. Katherine Panageas (6)
  3. Andriy Derkach (5)
  4. David Scheinberg (5)
  5. Gunjan Shah (5)
  6. Urvi Shah (5)

More People

Years
  1. 2023 (1)
  2. 2022 (3)
  3. 2021 (2)
  4. 2020 (1)
  5. 2016 (1)
  6. 2012 (1)

More Years

Publications
  1. Journal of Clinical Oncology (13)
Publishers
  1. American Society of Clinical Oncology (13)

Results (13)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP cohort
    Meeting Abstract

    Parikh, R.; Castro, F.; Eustaquio, J. C.; Derkach, A.; Joseph, J.; Lesokhin, A. M.; Usmani, S. Z.; Shah, U. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical efficacy of daratumumab (DARA)-based second line therapy after DARAcontaining and DARA-free induction therapies in multiple myeloma: A single center experience
    Meeting Abstract

    Ciardiello, A.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Lu, S. X.; Patel, D.; Maclachlan, K.; Lahoud, O. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Evaluating serum-free light chain ratio as a biomarker for multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients
    Meeting Abstract

    Hevroni, G.; Mastey, D.; Tavitian, E.; Derkach, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab
    Meeting Abstract

    Ghione, P.; Joffe, E.; De Paola, N.; Mainardi, T.; Noor, S. J.; Bobillo, S.; Myskowski, P. L.; Palomba, M. L.; Moskowitz, A. J.; Mato, A. R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Randomized phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy
    Meeting Abstract

    Zauderer, M. G.; Dao, T.; Rusch, V. W.; Ginsberg, M. S.; Tsao, A. S.; Panageas, K.; Stergiou, A. M.; Scheinberg, D. A.; Krug, L. M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma
    Meeting Abstract

    Kitano, S.; Postow, M. A.; Cortez, C.; Rasalan, T.; Gallardo, H. F.; Panageas, K.; Yuan, J.; Wolchok, J. D.; Lesokhin, A. M.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM)
    Meeting Abstract

    Krug, L. M.; Tsao, A. S.; Kass, S.; Rusch, V. W.; Travis, W. D.; Panageas, K.; Adusumili, P. S.; Kris, M. G.; Maslak, P. G.; Scheinberg, D. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save